Drug intelligence / Profile preview

3H-8000

Development stage: Preclinical
Lead developer: 3H Pharmaceuticals
Modality: Small Molecules

Overview

3H-8000 (also known as Project 8000) is a preclinical-stage small molecule drug candidate being developed by 3H (Shanghai) Pharmaceuticals Co., Ltd. for the treatment of cancer. The compound is part of the company's oncology pipeline, which focuses on developing innovative, highly selective, and potentially dual-targeted therapies. As of early 2024, specific molecular targets and the exact mechanism of action for 3H-8000 remain proprietary and have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on 3H-8000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3H-8000.

Explore the full profile